Aaron Davidson/Telemundo/NBCU Photo Bank via Getty Images
Ricky Martin at the 2021 Latin American Music Awards the BB&T Center in Sunrise, FL on April 15, 2021.
Ricky Martin and Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases and the chief medical advisor to the president, took center stage at the 2021 Latin AMAs – via Zoom chat – to talk about the importance of the Hispanic community getting vaccinated against COVID-19. Hispanics are disproportionally bearing the burden of COVID-19, so it s extremely important to get them vaccinated to protect themselves, their families and their community, explained Dr. Fauci.
Washington Post columnist
Anthony Fauci’s role in it, in an interview with
Megyn Kelly.
“This body of research, this gain-of-function research, the whole world of virologists … it’s very insular,” Rogin said in an interview on Kelly’s podcast. “I often talk to scientists who say the same thing, who say, ‘Listen, we really want to speak out about this, but we can’t do it.’ Why can’t we do it? Well, We get all of our funding from NIH, or NIAID, which is run by Dr. Fauci. … And so we can’t say anything like ‘Oh, gain-of-function research might be dangerous, or it might have come from a lab, because we’re going to lose our careers, we’re going to lose our funding, we’re not going to be able to do our work. ”
2021-04-16 04:05:48 GMT2021-04-16 12:05:48(Beijing Time) Xinhua English
BEIJING, April 16 (Xinhua) China s first messenger RNA (mRNA) COVID-19 vaccine will start its Phase III clinical trial in May, China National Radio (CNR) has reported.
The Phase II trial of the vaccine ARCoV, jointly developed by China s Suzhou Abogen Biosciences (AbogenBio), the Institute of Military Medicine under the Academy of Military Sciences and Walvax Biotechnology Co., Ltd, is running smoothly and drawing to a close, the CNR reported Tuesday, citing an exclusive telephone interview with Ying Bo, founder of AbogenBio.
The late-stage trial will begin next month overseas with close cooperation with Chinese clinical contract research organization Tigermed, the report said.
2021-04-16 11:35:50 GMT2021-04-16 19:35:50(Beijing Time) Xinhua English
SYDNEY, April 16 (Xinhua) A Brisbane and Seattle-based company said on Friday that a new therapeutic candidate for the treatment of COVID-19 patients will enter a clinical trial in the United States, led by Professor Ian Frazer, a former recipient of the Australian of the Year award.
Developed by biotechnology company Implicit Bioscience, the drug IC14 will be tested in more than 400 COVID-19 patients in 10 to 15 hospitals across the United States this week. Volunteer participants will be assigned at random to receive intravenous infusions of either IC14 or a placebo for four days.